 Positive results achieved in phase 1 study NTLA-2001 to treat ATTR-PN patients; 87 reduction of serum TTR levels in 3 patients using 0.3 mgkg and then 52 reduction using 0.1 mgkg. Additional results from this phase 1 study, using NTLA-2001 to treat ATTR-PN patients, is expected Q1 of 2022. 